ClinicalTrials.gg
CompletedNCT01306461Updated Jun 8, 2012

Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations

A Phase 3 interventional study of Timolol and Tafluprost and Fixed Dose Combination of tafluprost and timolol in Ocular Hypertension and Open-angle Glaucoma, sponsored by Santen Oy. Completed at 1 site in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-08.

Primary conditionGlaucoma, Open-AngleRegistry: Ocular HypertensionReclassifiedWhy we changed it
Registry
Ocular Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glaucoma, Open-Angle
Why
  1. The study's listed conditions name Glaucoma, Open-Angle, a narrower term within Ocular Hypertension.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Santen Oy (part of Santen Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
401
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd. — 1 open to participants now, 2 under way, 1 of them phase 3. Glaucoma, Open-Angle · Santen Pharmaceutical Co., Ltd..

Enrollment
4th of 31
401 · median 165
Started
2011
with 6 others
Phase 3
17 of 37
none open now
Registered
10th of 37
by date

Among the 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd., this one is the 4th largest by enrollment of the 31 interventional ones that give a count, is one of 7 that started in 2011, is one of 17 in phase 3, and was the 10th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

1 of the 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd. is open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost and timolol (FDC) to concomitant administration of tafluprost and timolol.

This study will enroll patients who have ocular hypertension or glaucoma.

The study schedule includes seven visits to the study site and three stages:

  • washout of 5 days to 4 weeks depending on current glaucoma medication (if any)
  • 6-month study treatment period
  • 1-3 weeks post-study period
03

Conditions studied

  • Ocular Hypertension
  • Open-angle Glaucoma

Browse trials for

04

In context

Glaucoma, Open-Angle Reclassified

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

This study's enrollment of 401 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Santen Oy is the lead sponsor of 8 studies on the registry; none are open to participants now.

Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ocular Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or more
  • A diagnosis of ocular hypertension or open-angle glaucoma
  • Meet specific IOP level at visit 1 (screening)and visit 2 (baseline)
  • Meet specific visual acuity score
  • Are willing to follow instructions
  • Have provided a written

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant, nursing or planning pregnancy
  • IOP greater than 36 mmHg at any time point at screening or baseline
  • Diagnosis of angle-closure glaucoma or secondary glaucoma other than capsular or pigmentary glaucoma in either eye
  • Suspected or to study medications tafluprost or timolol (e.g. asthma, low pulse) or to wash-out medication brinzolamide
  • Glaucoma filtration surgery or any other ocular surgery (including ocular laser procedures) within 6 months prior to Screening
  • Use of contact lenses at Screening or during the study
  • Presence of any abnormality or significant illness that could be expected to interfere with the patient safety or study parameters
  • Current participation in another clinical trial within the last 30 days
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
401 participants (actual)

Study arms

  • Active comparator
    Timolol and Tafluprost

    Concomitant administration of preservative-free timolol and tafluprost eye drops

    Drug: Timolol and Tafluprost

  • Experimental
    Fixed Dose Combination of tafluprost and timolol

    Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops

    Drug: Fixed Dose Combination of tafluprost and timolol

Interventions

  • DrugTimolol and Tafluprost

    Drug pages: Timolol · Tafluprost

    Preservative-free Timolol eye drops administered twice daily concomitantly with preservative-free Tafluprost eye drops administered once daily Treatment period 6 months

  • DrugFixed Dose Combination of tafluprost and timolol

    Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops administered once daily. For masking purposes also: vehicle for timolol administered twice daily Treatment period 6 months

07

What researchers measure

Primary outcomes

  1. Change from baseline in the average diurnal intra-ocular pressure (IOP) at 6 months

    Time frame: 6 months

Secondary outcomes

  1. Change from baseline in average diurnal IOP at 2 weeks, 6 weeks and 3 months

    Time frame: 2 weeks, 6 weeks and 3 months

  2. Change from baseline in timewise IOPs

    Change from baseline in timewise IOPs (at 8:00, 10:00, 16:00) at 2 weeks, 6 weeks, 3 months and 6 months

    Time frame: 2 weeks, 6 weeks, 3 months and 6 months

08

Study locations

1 site
  • Debrecen, Hungary
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Apr 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2011
First posted
Mar 1, 2011
Start
Mar 2011
Primary completionActual
Apr 2012
CompletionActual
May 2012
Last update
Jun 8, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01306461
Lead sponsor
Santen Oy
Responsible party
Sponsor
First posted
Mar 1, 2011
Start date
Mar 2011
Primary completion
Apr 2012
Completion
May 2012
Last update
Jun 8, 2012

Study contacts

Auli Ropo, M.D.
study director · Santen Oy
Clemens Vass, M.D.
principal investigator · Medical University Vienna, Austria
Marieta Kostianeva, M.D.
principal investigator · University Mulitiprofile Hospital for Active Treatment Sv.Georgi, Bulgaria
Eva Ruzickova, M.D.
principal investigator · Vseobecna fakultni nemocnice v Praze, Czech Republic
Gábor Holló
principal investigator · Semmelweis Egyetem, Hungary
Guna Laganovska, M.D.
principal investigator · P. Stradina Clinical University Hospital, Latvia
Maria L. Ribeiro, M.D.
principal investigator · Aibili-Associação p/ Investigação Biomédica e Inovação em Luz e Imagem (AIBILI), Portugal
Julián García-Feijóo, M.D.
principal investigator · Hospital Clinico San Carlos, Spain

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion